AbCellera Biologics Statistics Share Statistics AbCellera Biologics has 298.83M
shares outstanding. The number of shares has increased by 1.3%
in one year.
Shares Outstanding 298.83M Shares Change (YoY) 1.3% Shares Change (QoQ) 0.17% Owned by Institutions (%) 41.9% Shares Floating 202.75M Failed to Deliver (FTD) Shares 28,808 FTD / Avg. Volume 0.51%
Short Selling Information The latest short interest is 44.38M, so 14.85% of the outstanding
shares have been sold short.
Short Interest 44.38M Short % of Shares Out 14.85% Short % of Float 19.27% Short Ratio (days to cover) 11.28
Valuation Ratios The PE ratio is -5.3 and the forward
PE ratio is -10.11.
AbCellera Biologics's PEG ratio is
-0.68.
PE Ratio -5.3 Forward PE -10.11 PS Ratio 29.91 Forward PS 20.4 PB Ratio 0.82 P/FCF Ratio -4.61 PEG Ratio -0.68
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for AbCellera Biologics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 9.81,
with a Debt / Equity ratio of 0.06.
Current Ratio 9.81 Quick Ratio 9.81 Debt / Equity 0.06 Debt / EBITDA -0.32 Debt / FCF -0.35 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $48.38K Profits Per Employee $-273.25K Employee Count 596 Asset Turnover 0.02 Inventory Turnover n/a
Taxes Income Tax -37.54M Effective Tax Rate 18.73%
Stock Price Statistics The stock price has increased by 81.61% in the
last 52 weeks. The beta is 0.65, so AbCellera Biologics's
price volatility has been higher than the market average.
Beta 0.65 52-Week Price Change 81.61% 50-Day Moving Average 4.49 200-Day Moving Average 3.22 Relative Strength Index (RSI) 55.89 Average Volume (20 Days) 5,605,112
Income Statement In the last 12 months, AbCellera Biologics had revenue of 28.83M
and earned -162.86M
in profits. Earnings per share was -0.55.
Revenue 28.83M Gross Profit -68.17M Operating Income -314.77M Net Income -162.86M EBITDA -204.15M EBIT -301.15M Earnings Per Share (EPS) -0.55
Full Income Statement Balance Sheet The company has 156.32M in cash and 65.36M in
debt, giving a net cash position of 90.96M.
Cash & Cash Equivalents 156.32M Total Debt 65.36M Net Cash 90.96M Retained Earnings 116.93M Total Assets 1.4B Working Capital 675.12M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -108.56M
and capital expenditures -78.4M, giving a free cash flow of -186.95M.
Operating Cash Flow -108.56M Capital Expenditures -78.4M Free Cash Flow -186.95M FCF Per Share -0.64
Full Cash Flow Statement Margins Gross margin is -236.42%, with operating and profit margins of -1091.69% and -564.83%.
Gross Margin -236.42% Operating Margin -1091.69% Pretax Margin -695.02% Profit Margin -564.83% EBITDA Margin -708.04% EBIT Margin -1091.69% FCF Margin -648.4%
